Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD

2004824 citationsJournal Articlegreen Open Access

Authors

Clifford R. Jack · Mayo Clinic

Maria M. Shiung · Mayo Clinic

Jeffrey L. Gunter · Mayo Clinic

Peter C. O’Brien · Mayo Clinic

Stephen D. Weigand · Mayo Clinic

David S. Knopman · Mayo Clinic

Bradley F. Boeve · Mayo Clinic

Abstract

These data support the use of rates of change from serial MRI studies in addition to standard clinical/psychometric measures as surrogate markers of disease progression in AD. Estimated sample sizes required to power a therapeutic trial in MCI were an order of magnitude less for MRI than for change measures based on cognitive tests/rating scales.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Ginkgo biloba and Cashew Applications Dementia and Cognitive Impairment Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 62, Issue 4, pp. 591-600

DOI: 10.1212/01.wnl.0000110315.26026.ef

Field-Weighted Citation Impact: 30.34